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Abstract: X-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy are two powerful tools to determine the protein 3D structure. 
However, not all proteins can be successfully crystallized, particularly for 
membrane proteins. Although NMR spectroscopy is indeed very powerful in 
determining the 3D structures of membrane proteins, same as X-ray 
crystallography, it is still very time-consuming and expensive. Under many 
circumstances, due to the noncrystalline and insoluble nature of some 
proteins, X-ray and NMR cannot be used at all. Computational approaches, 
however, allow us to obtain a description of the protein 3D structure at a 
submicroscopic level. 
 
To the best of the authors’ knowledge, there is little structural data available to 
date on the AGAAAAGA palindrome in the hydrophobic region (113–120) of 
prion proteins, which falls just within the N-terminal unstructured region (1–
123) of prion proteins. Many experimental studies have shown that the 
AGAAAAGA region has amyloid fibril forming properties and plays an 
important role in prion diseases. Due to the noncrystalline and insoluble 
nature of the amyloid fibril, little structural data on the AGAAAAGA is available. 
This paper introduces a simple molecular modelling strategy to address the 
3D atomic-resolution structure of prion AGAAAAGA amyloid fibrils. Atomic-
resolution structures of prion AGAAAAGA amyloid fibrils got in this paper are 
useful for the drive to find treatments for prion diseases in the field of 
medicinal chemistry. 
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1 Introduction 
Prion diseases are invariably fatal and highly infectious neurodegenerative 
diseases affecting humans and animals. The neurodegenerative diseases 
such as Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob diseases 
(vCJD), iatrogenic CreutzfeldtJakob disease (iCJD), familial Creutzfeldt-Jakob 
disease (fCJD), sporadic Creutzfeldt-Jakob disease (sCJD), Gerstmann-
Straussler-Scheinker syndrome (GSS), Fatal Familial Insomnia (FFI), Kuru in 
humans, scrapie in sheep, bovine spongiform encephalopathy (BSE or mad-
cow disease) in cattle, chronic wasting disease (CWD) in white-tailed deer, elk, 
mule deer, moose, transmissible mink encephalopathy (TME) in mink, feline 
spongiform encephalopathy (FSE) in cat, exotic ungulate encephalopathy 
(EUE) in nyala, oryx, greater kudu, and spongiform encephalopathy (SE) in 
ostrich etc belong to prion diseases. By now there have not been some 
effective therapeutic approaches or medications to treat all these prion 
diseases. 
 
Prion diseases are amyloid fibril diseases. The normal cellular prion protein 
(PrPC) is rich in α-helices but the infectious prions (PrPSc) are rich in β-sheets 
amyloid fibrils. The conversion of PrPC to PrPSc is believed to involve a 
conformational change from a predominantly α-helical protein (about 42% α-
helix and 3% β-sheet) to a protein rich in β-sheets (about 30% α-helix and 
43% β-sheet) [1]. 
 
Many experimental studies such as [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12] have 
shown two points: (1) the hydrophobic region (113-120) AGAAAAGA of prion 
proteins is critical in the conversion from a soluble PrPC into an insoluble 
PrPSc fibrillar form; and (2) normal AGAAAAGA is an inhibitor/blocker of prion 
diseases. PrP lacking the palindrome could not convert to PrPSc and also did 
not generate proteinase-K resistance. The presence of residues 119 and 120 
(the two last residues within the motif AGAAAAGA) seems to be crucial for 
this inhibitory effect. The replacement of glycine at residues 114 and 119 by 
alanine led to the inability of the peptide to build fibrils but it nevertheless 
increased. The A117V variant is linked to the GSS disease. Etc.. Furthermore, 
we computationally clarified by ourselves that prion AGAAAAGA segment 
indeed has an amyloid fibril forming property [13, 14, 15]: Figure 1. 
 
< Figure 1 > 
Figure 1: Prion AGAAAAGA (113-120) is surely and clearly identified as the 
amyloid fibril formation region, because its energy is less than the amyloid 
fibril formation threshold energy of -26 kcal/mol [33]. 
 
By now the 3D structure of the AGAAAGA palindrome peptide has not been 
known. The physiological conditions such as pH [5] and temperature [16] will 
affect the propensity to form fibrils in this region. However, laboratory 
experiences have shown that using traditional experimental methods is very 
difficult to obtain atomic-resolution structures of AGAAAAGA due to the 
noncrystalline and insoluble nature of the amyloid fibril [17, 18] and its 
unstable nature. By introducing novel mathematical canonical dual 
formulations and computational approaches, in this paper we may construct 
atomic-resolution molecular structures for prion (113-120) AGAAAAGA 
amyloid fibrils. 
 
The 3D atomic resolution structure of PrP (106-126), i.e. 
TNVKHVAGAAAAGAVVGGLGG, can be looked as the structure of a control 
peptide [19, 20]. Ma and Nussinov (2002) established homology structure of 
AGAAAAGA and its molecular dynamics simulation studies [21]. Recently, 
Wagoner et al. studied the structure of GAVAAAAVAG of mouse prion protein 
[22, 16]. All these structures (including the structures of this current paper) of 
amyloid cross-β spines can be reduced to the ones of 8 classes of steric 
zippers reported in [23]. Thus, we might be able to say that the molecular 
modeling strategy reported in this study should be reliable. 
 
Many studies have indicated that computational approaches or introducing 
novel mathematical formulations and physical concepts into molecular biology 
can significantly stimulate the development of biological and medical science. 
Various computer computational approaches were used to address the 
problems related to “amyloid fibril” [24, 25, 26, 27, 28, 29]. Here, we would like 
to use the simulated annealing evolutionary computations to build the optimal 
atomic-resolution amyloid fibril models in hopes to be used for controlling 
prion diseases. The templates from the Protein Data Bank (pdb) 
(http://www.rcsb.org) and the modeling computational algorithms are different 
among this current study and previous studies [14, 15]. Zhang (2011) used all 
the pdb files of [23] and the Insight II package to establish the models [14]. 
Zhang et al. (2011) used 3FVA.pdb (the NNQNTF (173-178) segment from 
elk prion protein) and hybrid simulated annealing discrete gradient (SADG) 
method to build the models [15]. This current study uses 3NHC.pdb (the 
GYMLGS (127-132) segment from human M129 prion protein) as the 
modelling template and simulated annealing evolutionary computations 
(SAEC) to build the models, where SAECs were got from the hybrid 
algorithms of [30] by simply replacing the DG method by the SA algorithm of 
[31, 15] and numerical computational results show that SAECs can 
successfully pass the test of more than 40 well-known benchmark global 
optimization problems. 
 
The atomic structures of all amyloid fibrils revealed steric zippers, with strong 
van der Waals (vdw) interactions between β-sheets and hydrogen bonds (HBs) 
to maintain the β-strands [23]. The vdw contacts of atoms are described by 
the Lennard-Jones (LJ) potential energy: 
VLJ(r) = 4ε [(σ/r)12 - (σ/r)6],                  (Eq. 1) 
where ε is the depth of the potential well and σ is the atom diameter; these 
parameters can be fitted to reproduce experimental data or deduced from 
results of accurate quantum chemistry calculations. The (σ/r)12  term describes 
repulsion and the -(σ/r)6 term describes attraction. If we introduce the 
coordinates of the atoms whose number is denoted by N and let ε=σ= 1 be 
the reduced units, the formula (Eq. 1) becomes 
                               f(x) = 4 ∑i=1N  ∑j=1,j<iN  (1/tij6 - 1/tij3),    (Eq. 2) 
where tij = (x3i−2 – x3j−2)2  +  (x3i−1 – x3j−1)2  +  (x3i – x3j )2, (x3i−2, x3i−1, x3i) is the 
coordinates of atom i, N≥2. The minimization of LJ potential f(x) on Rn (where 
n = 3N) is an optimization problem: 
min f(x) subject to x € R3N.                   (Eq. 3) 
Similarly as (Eq. 1) – the potential energy for the vdw interactions between β-
sheets: 
                                   VLJ(r)  = A/r12 - B/r6,                      (Eq. 4) 
the potential energy for the HBs between the β-strands has the formula 
                                   VHB(r)  = C/r12 - D/r10,                    (Eq. 5) 
where A,B,C,D are given constants. Thus, the amyloid fibril molecular 
modelling problem is deduced into well solve the mathematical optimization 
problem (Eq. 3). 
 
This paper is organized as follows. In Section 2, we first describe how to build 
the prion AGAAAAGA amyloid fibril molecular models, and then explain how 
the models with only 6 variables are built and can be solved by any 
optimization algorithm. At the end of Section 2 the models are done a little 
refinement by Amber 11 [32]. At last, we conclude that when using the time-
consuming and costly X-ray crystallography or NMR spectroscopy we still 
cannot determine the protein 3D structure, we may introduce computational 
approaches or novel mathematical formulations and physical concepts into 
molecular biology to study molecular structures. This concluding remark will 
be made in the last section. 
 
2 Prion AGAAAAGA amyloid fibril models’Molecular 
Modeling and Optimizing 
 
Constructions of the AGAAAAGA amyloid fibril molecular structures of prion 
113–120 region are based on the most recently released experimental 
molecular structures of human M129 prion peptide 127–132 (PDB entry 
3NHC released into Protein Data Bank on 04-AUG-2010). The atomic-
resolution structure of this peptide is a steric zipper, with strong vdw 
interactions between β-sheets and HBs to maintain the β-strands (Figure 2). 
 
< Figure 2 > 
Figure 2: Protein fibril structure of human M129 prion GYMLGS (127–132) 
(PDB ID: 3NHC). The dashed lines denote the hydrogen bonds. A, B, ..., K, L 
denote the chains of the fibril. 
 
In Figure 2 we see that G (H) chains (i.e. β-sheet 2) of 3NHC.pdb can be 
obtained from A (B) chains (i.e. β-sheet 1) by 
 
G(H) =((1 0 0)T, (0 −1 0)T,  (0 0 −1)T) A(B) + (9.07500 4.77650 0.00000)T   (Eq. 6) 
 
and other chains can be got by 
 
       I(J) = G(H) +(0 9.5530 0)T, K(L) = G(H) +(0 −9.5530 0)T,                     (Eq. 7) 
 
       C(D) = A(B) +(0 9.5530 0)T, E(F) = A(B) +(0 −9.5530 0)T.                   (Eq. 8) 
 
Basing on the template 3NHC.pdb from the Protein Data Bank, three prion 
AGAAAAGA palindrome amyloid fibril models - an AAAAGA model (Model 1), 
a GAAAAG model (Model 2), and an AAAAGA model (Model 3) - will be 
successfully constructed in this paper. AB chains of Models 1-3 were 
respectively got from AB chains of 3NHC.pdb using the mutate module of the 
free package Swiss-PdbViewer (SPDBV Version 4.01) (http://spdbv.vital-it.ch). 
It is pleasant to see that almost all the hydrogen bonds are still kept after the 
mutations; thus we just need to consider the vdw contacts only. Making 
mutations for GH chains of 3NHC.pdb, we can get the GH chains of Models 
1-3. However, the vdw contacts between A chain and G chain, between B 
chain and H chain are too far at this moment (Figures 3-5). 
 
< Figure 3 > 
Figure 3: At initial state, the vdw contacts between AG chains (_-sheet 1) and 
BH chains (β-sheet 2) of Model 1 are very far. 
 
< Figure 4 > 
Figure 4: At initial state, the vdw contacts between AG chains (_-sheet 1) and 
BH chains (β-sheet 2) of Model 2 are very far. 
 
< Figure 5 > 
Figure 5: At initial state, the vdw contacts between AG chains (_-sheet 1) and 
BH chains (β-sheet 2) of Model 3 are very far. 
 
Seeing Figures 3-5, we may know that for Models 1-3 at least two vdw 
interactions between A.ALA3.CB-G.ALA4.CB, B.ALA4.CB-H.ALA3.CB should 
be maintained. Fixing the coordinates of A.ALA3.CB and B.ALA4.CB, letting 
the coordinates of G.ALA4.CB and H.ALA3.CB be variables, we may get a 
simple LJ potential energy minimization problem (Eq. 3) just with six variables. 
For solving this six variable optimization problem, any optimization 
computational algorithm can be used to solve this low-dimensional 
mathematical optimization problem; for example, in this paper we may use the 
SAEC algorithm. Setting the coordinates of G.ALA4.CB and H.ALA3.CB as 
initial solutions, running a SAEC algorithm, for Models 1-3 we get 
 
G(H) =((1 0 0)T, (0 −1 0)T,  (0 0 −1)T) A(B) + (−0.703968 7.43502 −0.33248)T.  (Eq. 9) 
 
By (Eq. 9) we can get close vdw contacts between A chain and G chain, 
between B chain and H chain (Figures 6-8). 
 
< Figure 6 > 
Figure 6: After LJ potential energy minimization, the vdw contacts between 
AG chains (β-sheet 1) and BH chains (β-sheet 2) of Model 1 become very 
closer. 
 
< Figure 7 > 
Figure 7: After LJ potential energy minimization, the vdw contacts between 
AG chains (β-sheet 1) and BH chains (β-sheet 2) of Model 2 become very 
closer. 
 
< Figure 8 > 
Figure 8: After LJ potential energy minimization, the vdw contacts between 
AG chains (β-sheet 1) and BH chains (β-sheet 2) of Model 3 become very 
closer. 
 
Furthermore, we may employ the Amber 11 package [32] to slightly optimize 
Models 1-3 and at last get Models 1-3 with stable total potential energies 
(Figures 9-11). The other CDIJ and EFKL chains can be got by parallelizing 
ABGH chains in the use of mathematical formulas (Eq. 7)-(Eq. 8). 
 
< Figure 9 > 
Figure 9: After Amber 11 refinement of the whole potential energy 
minimization, the optimal structure of prion AGAAAA amyloid fibril Models 1. 
 
< Figure 10 > 
Figure 10: After Amber 11 refinement of the whole potential energy 
minimization, the optimal structure of prion GAAAAG amyloid fibril Models 2. 
 
< Figure 11 > 
Figure 11: After Amber 11 refinement of the whole potential energy 
minimization, the optimal structure of prion AAAAGA amyloid fibril Models 3. 
 
3 Conclusion 
 
X-ray crystallography is a powerful tool to determine the protein 3D structure. 
However, it is time-consuming and expensive, and not all proteins can be 
successfully crystallized, particularly for membrane proteins. Although NMR 
spectroscopy is indeed a very powerful tool in determining the 3D structures 
of membrane proteins, it is also time-consuming and costly. Due to the 
noncrystalline and insoluble nature of the amyloid fibril, little structural data on 
the prion AGAAAAGA segment is available. Under these circumstances, the 
novel simple strategy introduced in this paper can well do the molecular 
modeling of prion AGAAAAGA amyloid fibrils. This indicated that 
computational approaches or introducing novel mathematical formulations 
and physical concepts into molecular biology can significantly stimulate the 
development of biological and medical science. The optimal atomic-resolution 
structures of prion AGAAAAGA amyloid fibils presented in this paper are 
useful for the drive to find treatments for prion diseases in the field of 
medicinal chemistry. 
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